SynOx Therapeutics, a Dublin, Ireland- and Oxford, UK-based late clinical-stage biopharmaceutical company developing a novel treatment for CSF-1 related and macrophage-driven disorders, raised additional funding in Series B round.
The round, which brought the total amount to $92M, was led by Gilde Healthcare with participation from Forbion, HealthCap and Bioqube Ventures. As part of the Series B extension, Arthur Franken, general partner at Gilde Healthcare, will join the SynOx Board of Directors. Mr. Franken brings more than two decades of venture and growth capital investment expertise, including several public listings and trade sales.
The company intends to use the funds to support a registrational Phase 3 clinical trial of emactuzumab, a CSF-1 receptor (CSF-1R) inhibiting monoclonal antibody for the treatment of Tenosynovial Giant Cell Tumour (TGCT).
Led by CEO Ray Barlow, SynOx Therapeutics is a late clinical-stage biopharmaceutical company developing emactuzumab, a monoclonal antibody against CSF-1R, for the treatment of Tenosynovial Giant Cell Tumour (TGCT) and other CSF-1 related and macrophage driven disorders.
In conjunction with the closing of the Series B extension, SynOx today announced that the first patients have been dosed in its Phase 3 registrational study of emactuzumab. The study, named TANGENT, is a global, multi-centre, randomized, double-blind, placebo-controlled Phase 3 trial designed to evaluate the efficacy and safety of emactuzumab in patients with TGCT. Its primary outcome measure is overall response rate (ORR). Investigators will also assess several secondary outcomes including functional and quality of life measurements, impact on tumour volume, and duration of response. Investigators expect to enrol approximately 130 patients in the trial.
FinSMEs
30/10/2024